Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery
NCT ID: NCT03317119
Last Updated: 2024-04-08
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE1
Total Enrollment
26 participants
Study Classification
INTERVENTIONAL
Study Start Date
2018-04-11
Study Completion Date
2023-07-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This phase I trial studies the side effects and best dose of trametinib and trifluridine and tipiracil hydrochloride in treating patients with colon or rectal cancer that has spread to other places in the body (advanced/metastatic) or cannot be removed by surgery. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as trifluridine and tipiracil hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving trametinib and trifluridine and tipiracil hydrochloride may prevent cancer cells from dividing and work better in treating patients with colon and rectal cancer.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer
NCT04511039
Advanced Malignant Solid Neoplasm
Clinical Stage III Gastroesophageal Junction Adenocarcinoma
Clinical Stage IV Gastroesophageal Junction Adenocarcinoma
+26 more
RECRUITING
PHASE1
Evaluating Trifluridine/Tipiracil Based Chemoradiation in Locally Advanced Rectal Cancer - The Phase I/II TARC Trial
NCT04177602
Locally Advanced Rectal Cancer
TERMINATED
PHASE1/PHASE2
Trametinib, Fluorouracil, and Radiation Therapy Before Surgery in Treating Patients With Stage II-III Rectal Cancer
NCT01740648
Recurrent Rectal Cancer
Stage IIA Rectal Cancer
Stage IIB Rectal Cancer
+4 more
COMPLETED
PHASE1
Combination Chemotherapy Plus Trastuzumab in Treating Patients With Advanced, Recurrent, or Metastatic Colorectal Cancer
NCT00006015
Colorectal Cancer
TERMINATED
PHASE2
Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metastatic, Refractory Colorectal Cancer
NCT06654037
Metastatic Microsatellite Stable Colorectal Carcinoma
Refractory Microsatellite Stable Colorectal Carcinoma
Stage IV Colorectal Cancer AJCC v8
RECRUITING
PHASE1
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
PRIMARY OBJECTIVES:
I. Determine the maximum tolerated dose (MTD) for the combination of trametinib and trifluridine and tipiracil hydrochloride (TAS-102) in patients with chemotherapy-resistant metastatic colorectal cancer.
SECONDARY OBJECTIVES:
I. Describe the safety of the combination of trametinib and TAS-102 across all investigated dose levels.
II. Describe the clinical activity including objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) of the combination in an expansion cohort using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria.
OUTLINE:
Patients receive trifluridine and tipiracil hydrochloride orally (PO) twice daily (BID) on days 1-5 and 8-12 and trametinib PO once daily (QD) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 30 days and then bi-annually thereafter.
I. Determine the maximum tolerated dose (MTD) for the combination of trametinib and trifluridine and tipiracil hydrochloride (TAS-102) in patients with chemotherapy-resistant metastatic colorectal cancer.
SECONDARY OBJECTIVES:
I. Describe the safety of the combination of trametinib and TAS-102 across all investigated dose levels.
II. Describe the clinical activity including objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) of the combination in an expansion cohort using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria.
OUTLINE:
Patients receive trifluridine and tipiracil hydrochloride orally (PO) twice daily (BID) on days 1-5 and 8-12 and trametinib PO once daily (QD) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 30 days and then bi-annually thereafter.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Metastatic Colon Carcinoma
Metastatic Colorectal Carcinoma
Metastatic Rectal Carcinoma
RAS Family Gene Mutation
Stage III Colon Cancer AJCC v7
Stage III Colorectal Cancer AJCC v7
Stage III Rectal Cancer AJCC v7
Stage IIIA Colon Cancer AJCC v7
Stage IIIA Colorectal Cancer AJCC v7
Stage IIIA Rectal Cancer AJCC v7
Stage IIIB Colon Cancer AJCC v7
Stage IIIB Colorectal Cancer AJCC v7
Stage IIIB Rectal Cancer AJCC v7
Stage IIIC Colon Cancer AJCC v7
Stage IIIC Colorectal Cancer AJCC v7
Stage IIIC Rectal Cancer AJCC v7
Stage IV Colon Cancer AJCC v7
Stage IV Colorectal Cancer AJCC v7
Stage IV Rectal Cancer AJCC v7
Stage IVA Colon Cancer AJCC v7
Stage IVA Colorectal Cancer AJCC v7
Stage IVA Rectal Cancer AJCC v7
Stage IVB Colon Cancer AJCC v7
Stage IVB Colorectal Cancer AJCC v7
Stage IVB Rectal Cancer AJCC v7
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment (TAS-102, trametinib)
Patients receive trifluridine and tipiracil hydrochloride PO BID on days 1-5 and 8-12 and trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Group Type
EXPERIMENTAL
Laboratory Biomarker Analysis
Intervention Type
OTHER
Correlative studies
Trametinib
Intervention Type
DRUG
Given PO
Trifluridine and Tipiracil Hydrochloride
Intervention Type
DRUG
Given PO
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Laboratory Biomarker Analysis
Correlative studies
Intervention Type
OTHER
Trametinib
Given PO
Intervention Type
DRUG
Trifluridine and Tipiracil Hydrochloride
Given PO
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
GSK1120212
JTP-74057
MEK Inhibitor GSK1120212
Mekinist
Lonsurf
TAS 102
TAS-102
Tipiracil Hydrochloride Mixture with Trifluridine
Trifluridine/Tipiracil
Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* All subjects must have the ability to understand and the willingness to sign a written informed consent
* All patients must be able to take oral medications
* All patients must be deemed by investigator to have the initiative and means to be compliant with the study protocol (treatment and follow-up)
* Eastern Cooperative Oncology Group (ECOG) performance status =\< 2
* Pathologically confirmed advanced, unresectable, or metastatic colon or rectal cancer who have had intolerance to or progression after a fluoropyrimidine, oxaliplatin, irinotecan, and cetuximab or panitumumab in the event of wild-type RAS/BRAF tumors
* Of note, prior bevacizumab or regorafenib exposure is not mandated as some patients are deemed poor candidates for anti-angiogenesis therapy and never receive these agents
* Tumors must have undergone expanded molecular profiling with a Clinical Laboratory Improvement Act (CLIA)-certified platform that evaluates, at a minimum, RAS, PIK3CA, PTEN and BRAF mutations status
* Documented RAS-mutated tumor without activating PIK3CA mutations or PTEN mutation (loss of PTEN or silencing)
* Measurable disease by RECIST 1.1 guidelines
* Last chemotherapy at least 3 weeks from initiation of study treatment
* No investigational agents within 4 weeks from initiation of study treatment
* Negative serum or urine beta-human chorionic gonadotropin (HcG) test (female patient of childbearing potential only) performed within 72 hours of prior to first study dose
* Absolute neutrophil count (ANC) \>= 1500/mm\^3 (to be performed within 28 days prior to day 1 of protocol therapy)
* NOTE: Growth factor is not permitted within 14 days of ANC assessment unless cytopenia is secondary to disease involvement
* Platelets \>= 75,000/mm\^3 without transfusions (to be performed within 28 days prior to day 1 of protocol therapy)
* Hemoglobin (Hgb) \>= 8 g/dL without transfusions (to be performed within 28 days prior to day 1 of protocol therapy)
* Total serum bilirubin \< upper limit of normal (ULN) (to be performed within 28 days prior to day 1 of protocol therapy)
* Aspartate aminotransferase (AST) =\< 2.5 x ULN if no liver metastases or =\< 5 x ULN if liver metastases (to be performed within 28 days prior to day 1 of protocol therapy)
* Alanine aminotransferase (ALT) =\< 2.5 x ULN if no liver metastases or =\< 5 x ULN if liver metastases (to be performed within 28 days prior to day 1 of protocol therapy)
* Creatinine \< 1.5 x ULN or creatinine clearance of \>= 60 mL/min per the Cockcroft-Gault formula (to be performed within 28 days prior to day 1 of protocol therapy)
* Female of childbearing potential: negative urine or serum pregnancy test (to be performed within 28 days prior to day 1 of protocol therapy)
* If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
* Corrected QT (QTc) interval =\< 480 ms (12 lead-electrocardiography \[ECG\]) (to be performed within 28 days prior to day 1 of protocol therapy)
* Left ventricular ejection fraction \>= 50% as determined by multigated acquisition (MUGA) scan or echocardiogram (to be performed within 28 days prior to day 1 of protocol therapy)
* Normal eye examination (to be performed within 28 days prior to day 1 of protocol therapy)
* Women of childbearing potential must use highly effective methods of contraception throughout the study and for 4 months after study drug discontinuation
* Sexually active men must use a condom during intercourse while taking study drug and for 60 days after study drug discontinuation; a condom is required for vasectomized men to prevent delivery of study drug via seminal fluid
* All patients must be able to take oral medications
* All patients must be deemed by investigator to have the initiative and means to be compliant with the study protocol (treatment and follow-up)
* Eastern Cooperative Oncology Group (ECOG) performance status =\< 2
* Pathologically confirmed advanced, unresectable, or metastatic colon or rectal cancer who have had intolerance to or progression after a fluoropyrimidine, oxaliplatin, irinotecan, and cetuximab or panitumumab in the event of wild-type RAS/BRAF tumors
* Of note, prior bevacizumab or regorafenib exposure is not mandated as some patients are deemed poor candidates for anti-angiogenesis therapy and never receive these agents
* Tumors must have undergone expanded molecular profiling with a Clinical Laboratory Improvement Act (CLIA)-certified platform that evaluates, at a minimum, RAS, PIK3CA, PTEN and BRAF mutations status
* Documented RAS-mutated tumor without activating PIK3CA mutations or PTEN mutation (loss of PTEN or silencing)
* Measurable disease by RECIST 1.1 guidelines
* Last chemotherapy at least 3 weeks from initiation of study treatment
* No investigational agents within 4 weeks from initiation of study treatment
* Negative serum or urine beta-human chorionic gonadotropin (HcG) test (female patient of childbearing potential only) performed within 72 hours of prior to first study dose
* Absolute neutrophil count (ANC) \>= 1500/mm\^3 (to be performed within 28 days prior to day 1 of protocol therapy)
* NOTE: Growth factor is not permitted within 14 days of ANC assessment unless cytopenia is secondary to disease involvement
* Platelets \>= 75,000/mm\^3 without transfusions (to be performed within 28 days prior to day 1 of protocol therapy)
* Hemoglobin (Hgb) \>= 8 g/dL without transfusions (to be performed within 28 days prior to day 1 of protocol therapy)
* Total serum bilirubin \< upper limit of normal (ULN) (to be performed within 28 days prior to day 1 of protocol therapy)
* Aspartate aminotransferase (AST) =\< 2.5 x ULN if no liver metastases or =\< 5 x ULN if liver metastases (to be performed within 28 days prior to day 1 of protocol therapy)
* Alanine aminotransferase (ALT) =\< 2.5 x ULN if no liver metastases or =\< 5 x ULN if liver metastases (to be performed within 28 days prior to day 1 of protocol therapy)
* Creatinine \< 1.5 x ULN or creatinine clearance of \>= 60 mL/min per the Cockcroft-Gault formula (to be performed within 28 days prior to day 1 of protocol therapy)
* Female of childbearing potential: negative urine or serum pregnancy test (to be performed within 28 days prior to day 1 of protocol therapy)
* If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
* Corrected QT (QTc) interval =\< 480 ms (12 lead-electrocardiography \[ECG\]) (to be performed within 28 days prior to day 1 of protocol therapy)
* Left ventricular ejection fraction \>= 50% as determined by multigated acquisition (MUGA) scan or echocardiogram (to be performed within 28 days prior to day 1 of protocol therapy)
* Normal eye examination (to be performed within 28 days prior to day 1 of protocol therapy)
* Women of childbearing potential must use highly effective methods of contraception throughout the study and for 4 months after study drug discontinuation
* Sexually active men must use a condom during intercourse while taking study drug and for 60 days after study drug discontinuation; a condom is required for vasectomized men to prevent delivery of study drug via seminal fluid
Exclusion Criteria
* Prior chemotherapy, biologic, targeted, or radiotherapy within 3 weeks prior to entering study or not recovered from grade \>= 2 adverse events (AEs) due to agents administered more than 4 weeks earlier (except alopecia or neuropathy)
* Prior MEK inhibitor or prior TAS-102 therapy
* Use of other investigational drugs
* History or current evidence of retinal vein occlusion (RVO) or current risk factors for RVO (e.g., uncontrolled glaucoma or ocular hypertension, history of hyperviscosity, or hypercoagulability syndromes)
* History of retinal degenerative disease
* History of Gilbert's syndrome
* Previous or concurrent malignancy with the following exceptions:
* Adequately treated basal cell or squamous cell carcinoma of skin with adequate wound healing prior to study entry
* In situ carcinoma of the cervix treated curatively and without evidence of recurrence
* Primary malignancy completely resected and in complete remission \>= 1 year
* History of acute coronary syndromes (including myocardial infarction, unstable angina, coronary artery bypass graft, coronary angioplasty, or stenting) \< 6 months prior to screening
* Impaired cardiovascular function or clinically significant cardiovascular disease including any of the following: symptomatic congestive heart failure, clinically significant cardiac arrhythmias and/or conduction abnormalities \< 6 months prior to screening except for atrial fibrillation and paroxysmal supraventricular tachycardia
* Uncontrolled arterial hypertension despite appropriate medical therapy (systolic blood pressure \> 160 or diastolic blood pressure \> 100)
* Neuromuscular disorders associated with elevated creatine kinase (CK, e.g., inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis, or spinal muscular atrophy)
* Started or planning to start on strenuous exercise regimen after first dose of study treatment (i.e., muscular activities, such as strenuous exercise, that can result in significant increase in plasma CK levels should be avoided while on trametinib treatment)
* Gastrointestinal (GI) disease or impairment of GI function (e.g., active ulcerative disease, uncontrolled nausea, vomiting, or diarrhea, malabsorption syndrome, or small bowel resection)
* Prior major surgery =\< 3 weeks before study drug or not recovered from side effects of such procedure
* Ongoing grade \>= 3 neuropathy
* Known hypersensitivity to any components of study drugs
* Prior intolerance to a fluoropyrimidine
* Any other condition that would, in the investigator's judgement, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures (e.g., infection/inflammation, intestinal obstruction, unable to swallow medications, social/psychological issues, etc.)
* Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)
* Prior MEK inhibitor or prior TAS-102 therapy
* Use of other investigational drugs
* History or current evidence of retinal vein occlusion (RVO) or current risk factors for RVO (e.g., uncontrolled glaucoma or ocular hypertension, history of hyperviscosity, or hypercoagulability syndromes)
* History of retinal degenerative disease
* History of Gilbert's syndrome
* Previous or concurrent malignancy with the following exceptions:
* Adequately treated basal cell or squamous cell carcinoma of skin with adequate wound healing prior to study entry
* In situ carcinoma of the cervix treated curatively and without evidence of recurrence
* Primary malignancy completely resected and in complete remission \>= 1 year
* History of acute coronary syndromes (including myocardial infarction, unstable angina, coronary artery bypass graft, coronary angioplasty, or stenting) \< 6 months prior to screening
* Impaired cardiovascular function or clinically significant cardiovascular disease including any of the following: symptomatic congestive heart failure, clinically significant cardiac arrhythmias and/or conduction abnormalities \< 6 months prior to screening except for atrial fibrillation and paroxysmal supraventricular tachycardia
* Uncontrolled arterial hypertension despite appropriate medical therapy (systolic blood pressure \> 160 or diastolic blood pressure \> 100)
* Neuromuscular disorders associated with elevated creatine kinase (CK, e.g., inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis, or spinal muscular atrophy)
* Started or planning to start on strenuous exercise regimen after first dose of study treatment (i.e., muscular activities, such as strenuous exercise, that can result in significant increase in plasma CK levels should be avoided while on trametinib treatment)
* Gastrointestinal (GI) disease or impairment of GI function (e.g., active ulcerative disease, uncontrolled nausea, vomiting, or diarrhea, malabsorption syndrome, or small bowel resection)
* Prior major surgery =\< 3 weeks before study drug or not recovered from side effects of such procedure
* Ongoing grade \>= 3 neuropathy
* Known hypersensitivity to any components of study drugs
* Prior intolerance to a fluoropyrimidine
* Any other condition that would, in the investigator's judgement, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures (e.g., infection/inflammation, intestinal obstruction, unable to swallow medications, social/psychological issues, etc.)
* Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Sponsor Role
collaborator
City of Hope Medical Center
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Marwan G Fakih
Role: PRINCIPAL_INVESTIGATOR
City of Hope Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
City of Hope Corona
Corona, California, United States
Site Status
City of Hope Medical Center
Duarte, California, United States
Site Status
City of Hope Antelope Valley
Lancaster, California, United States
Site Status
City of Hope Mission Hills
Mission Hills, California, United States
Site Status
City of Hope Rancho Cucamonga
Rancho Cucamonga, California, United States
Site Status
City of Hope - Santa Clarita
Santa Clarita, California, United States
Site Status
City of Hope South Pasadena
South Pasadena, California, United States
Site Status
City of Hope West Covina
West Covina, California, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Chuang J, Gong J, Li SM, Wang C, Fakih M. A Phase I Clinical Trial of Trametinib in Combination with TAS-102 in Patients with Chemotherapy-Resistant RAS-Mutated (PIK3CA/PTEN-Wild Type) Metastatic Colorectal Cancer. Clin Colorectal Cancer. 2022 Sep;21(3):252-258. doi: 10.1016/j.clcc.2022.05.004. Epub 2022 May 23.
Reference Type
DERIVED
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2017-01923
Identifier Type: REGISTRY
Identifier Source: secondary_id
17212
Identifier Type: OTHER
Identifier Source: secondary_id
17212
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Trifluridine/Tipiracil and Irinotecan for the Treatment of Advanced Refractory Biliary Tract Cancer
NCT04072445
COMPLETED
PHASE2
Efficacy and Safety of Trifluridine/Tipiracil Combined With Fufuquitinib for Third-line Treatment of mCRC
NCT06485713
RECRUITING
PHASE2
Combination Chemotherapy in Treating Patients With Recurrent or Metastatic Colorectal Cancer
NCT00003001
UNKNOWN
PHASE1/PHASE2
A Study of Trifluridine/Tipiracil (Also Known as S 95005 or TAS-102) in Patients With a Pretreated Colorectal Cancer That Has Spread (Metastatic).
NCT03306394
COMPLETED
PHASE3
Trifluridine/Tipiracil Plus Regorafenib vs Trifluridine/Tipiracil Plus Bevacizumab for Refractory Metastatic Colorectal Cancer
NCT06992648
RECRUITING
PHASE3
Combination Chemotherapy in Treating Patients With Recurrent or Metastatic Colorectal Cancer
NCT00003287
COMPLETED
PHASE3
Hepatic Arterial Infusion of Floxuridine, Gemcitabine Hydrochloride, and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer Previously Treated With Surgery
NCT00645710
COMPLETED
PHASE1/PHASE2
Combination Chemotherapy in Treating Patients With Resected Colon Cancer
NCT00378716
COMPLETED
PHASE3
Trifluridine/Tipiracil Plus Fruquintinib vs. Trifluridine/Tipiracil Plus Bevacizumab in Refractory Metastatic Colorectal Cancer: A Randomized, Controlled, Open-Label, Non-Inferiority Trial
NCT07261709
NOT_YET_RECRUITING
PHASE2
Suberoylanilide Hydroxamic Acid, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Progressive Metastatic or Unresectable Colorectal Cancer or Other Solid Tumors
NCT00138177
COMPLETED
PHASE1
Intermittent or Continuous Panitumumab Plus FOLFIRI for RAS/B-RAF Wild-type Metastatic Colorectal Cancer
NCT04425239
COMPLETED
PHASE2
Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas
NCT03783936
COMPLETED
PHASE2
FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer
NCT02508077
TERMINATED
PHASE2
A Trial of an Investigational Drug for the Prevention of Diarrhea Associated With Irinotecan/5FU/Leucovorin Chemotherapy in Previously Untreated Metastatic Colorectal Cancer
NCT00040391
TERMINATED
PHASE2
Oxaliplatin, Irinotecan, and Capecitabine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Cannot Be Removed By Surgery
NCT00217711
COMPLETED
PHASE1/PHASE2
ChronoFOLFOX Plus Avastin for Patients With Metastatic Colorectal Cancer
NCT00385021
TERMINATED
PHASE2
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
NCT06662786
RECRUITING
PHASE3
Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer
NCT03844620
ACTIVE_NOT_RECRUITING
PHASE2
A Randomized Trial of Avastin + Gemcitabine + 5-Fluorouracil (5FU)/Folinic Acid Versus Avastin + Oxaliplatin + 5FU/Folinic Acid in Metastatic Colorectal Cancer
NCT00192075
COMPLETED
PHASE2
Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer
NCT06245356
RECRUITING
PHASE2
Chemotherapy With Raltitrexed and Fluorouracil in Treating Patients With Advanced Colorectal Cancer
NCT00002828
COMPLETED
PHASE1
CMAB009 Combined With FOLFIRI First-line Treatment in Patients With RAS/BRAF Wild-type, Metastatic Colorectal Cancer
NCT03206151
COMPLETED
PHASE3
Trifluridine/Tipiracil in Combination With Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients.
NCT04564898
ACTIVE_NOT_RECRUITING
PHASE1/PHASE2
Combination Chemotherapy in Treating Patients With Colorectal Cancer
NCT00039208
COMPLETED
PHASE2
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
NCT03872947
ACTIVE_NOT_RECRUITING
PHASE1